Literature DB >> 19022235

Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.

T Smuc1, T Lanisnik Rizner.   

Abstract

Estrogen action is regulated at the receptor level by regulation of expression of estrogen receptors, and at the pre-receptor level by interconversions between the active hormone (estradiol) and its inactive counterparts (estrone, estrone-sulfate). In peripheral tissues, estrogens can be produced via the aromatase or the sulfatase pathways. Aromatase converts androstenedione and testosterone to estrone and estradiol, respectively, and sulfatase releases estrogens from inactive sulfates, while sulfotransferase catalyzes the reverse reaction. In both pathways, 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) are of paramount importance as they catalyze activation of estrone to estradiol and inactivation of estradiol to estrone. These enzymes belong to either the short-chain dehydrogenase/reductase (SDR) or the aldo-keto reductase (AKR) protein superfamilies. Differential expression of these pre-receptor regulatory enzymes can lead to high estradiol concentrations, which have been implicated in the development of different diseases. Here, we have examined gene expression levels of estrogen-metabolizing enzymes, as six SDRs (17beta-HSD types 1, 2, 4, 7, 8, 12) and one AKR (17beta-HSD type 5; AKR1C3), of aromatase, steroid sulfatase (STS) and estrogen sulfotransferase (SULT1E1), and of the alpha and beta estrogen receptors (ERs), in breast cancer (MCF-7), endometrial cancer (Ishikawa), choriocarcinoma (JEG3) and liver cancer (HepG2) cell lines. After RNA isolation and cDNA synthesis, real-time PCR analyses were performed. The expression of AKR1C3 was examined also at the protein level. Our data show that in all four cancer cell lines, estradiol can be synthesized from estrone by the action of 17beta-HSD type 12, or from estrone-sulfate by sulfatase. In JEG3 and HepG2 cells, estradiol can be formed from androgens by aromatase and 17beta-HSD type 1. Also in HepG2 cells, AKR1C3, which converts androstenedione to testosterone, in concert with aromatase might be responsible for estradiol formation. In MCF7 and Ishikawa cells, estradiol exerts its actions through ERalpha, while in JEG3 and HepG2 cells, it may act through non-ER-mediated pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022235     DOI: 10.1016/j.cbi.2008.10.038

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  10 in total

1.  Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208.

Authors:  Xi-wei Ji; Guang-ping Chen; Yan Song; Ming Hua; Li-jie Wang; Liang Li; Yin Yuan; Si-yuan Wang; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

2.  Immunohistochemical analysis of 17β-hydroxysteroid dehydrogenase isozymes in human ovarian surface epithelium and epithelial ovarian carcinoma.

Authors:  Ken-ichi Motohara; Hironori Tashiro; Yumiko Taura; Takashi Ohba; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2011-01-26       Impact factor: 2.309

3.  Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.

Authors:  Craig L Doig; Sebastiano Battaglia; Farhat L Khanim; Christopher M Bunce; Moray J Campbell
Journal:  J Steroid Biochem Mol Biol       Date:  2015-09-30       Impact factor: 4.292

4.  The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.

Authors:  Aurora Shehu; Constance Albarracin; Y Sangeeta Devi; Kristin Luther; Julia Halperin; Jamie Le; Jifang Mao; Rachel W Duan; Jonna Frasor; Geula Gibori
Journal:  Mol Endocrinol       Date:  2011-03-03

5.  Shu-Gan-Liang-Xue Decoction Simultaneously Down-regulates Expressions of Aromatase and Steroid Sulfatase in Estrogen Receptor Positive Breast Cancer Cells.

Authors:  Xue-Song Fu; Ping-Ping Li
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

6.  17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.

Authors:  Juliette A Aka; Mouna Zerradi; François Houle; Jacques Huot; Sheng-Xiang Lin
Journal:  Breast Cancer Res       Date:  2012-06-12       Impact factor: 6.466

7.  Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1.

Authors:  Vineetha Koroth Edavana; Xinfeng Yu; Ishwori B Dhakal; Suzanne Williams; Baitang Ning; Ian T Cook; David Caldwell; Charles N Falany; Susan Kadlubar
Journal:  Pharmgenomics Pers Med       Date:  2011-11-16

8.  The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells.

Authors:  Chen-Yan Zhang; Jiong Chen; Da-Chuan Yin; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2012-01-09       Impact factor: 3.240

9.  Immunoexpression of aromatase cytochrome P450 and 17β-hydroxysteroid dehydrogenase in women's ovaries after menopause.

Authors:  Agnieszka Brodowska; Jacek Brodowski; Maria Laszczyńska; Sylwia Słuczanowska-Głąbowska; Bogdan Rumianowski; Iwona Rotter; Andrzej Starczewski; Mariusz Z Ratajczak
Journal:  J Ovarian Res       Date:  2014-05-10       Impact factor: 4.234

10.  Modulation of CYP19 expression by cabbage juices and their active components: indole-3-carbinol and 3,3'-diindolylmethene in human breast epithelial cell lines.

Authors:  Barbara E Licznerska; Hanna Szaefer; Marek Murias; Agnieszka Bartoszek; Wanda Baer-Dubowska
Journal:  Eur J Nutr       Date:  2012-10-23       Impact factor: 5.614

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.